MA44880A - Formes polymorphes de 3-[2-butyl-1-(2-diéthylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide et leurs utilisations - Google Patents

Formes polymorphes de 3-[2-butyl-1-(2-diéthylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide et leurs utilisations

Info

Publication number
MA44880A
MA44880A MA044880A MA44880A MA44880A MA 44880 A MA44880 A MA 44880A MA 044880 A MA044880 A MA 044880A MA 44880 A MA44880 A MA 44880A MA 44880 A MA44880 A MA 44880A
Authority
MA
Morocco
Prior art keywords
benzoimidazol
diethylamino
acrylamide
hydroxy
butyl
Prior art date
Application number
MA044880A
Other languages
English (en)
French (fr)
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA44880A publication Critical patent/MA44880A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044880A 2016-05-02 2017-05-01 Formes polymorphes de 3-[2-butyl-1-(2-diéthylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide et leurs utilisations MA44880A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02

Publications (1)

Publication Number Publication Date
MA44880A true MA44880A (fr) 2021-03-17

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044880A MA44880A (fr) 2016-05-02 2017-05-01 Formes polymorphes de 3-[2-butyl-1-(2-diéthylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide et leurs utilisations

Country Status (20)

Country Link
US (2) US10626092B2 (enExample)
EP (2) EP3939966A1 (enExample)
JP (1) JP2019514905A (enExample)
KR (1) KR20190005904A (enExample)
CN (1) CN109414425A (enExample)
AR (1) AR108257A1 (enExample)
AU (1) AU2017261218A1 (enExample)
BR (1) BR112018072439A2 (enExample)
CA (1) CA3022011A1 (enExample)
CL (1) CL2018003109A1 (enExample)
CO (1) CO2018012941A2 (enExample)
EA (1) EA201892341A1 (enExample)
ES (1) ES2886495T3 (enExample)
IL (1) IL262578A (enExample)
MA (1) MA44880A (enExample)
MX (1) MX382095B (enExample)
PH (1) PH12018502296B1 (enExample)
SG (1) SG11201809471UA (enExample)
TW (1) TW201741286A (enExample)
WO (1) WO2017192451A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291071B (zh) * 2017-02-28 2022-04-26 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) * 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003066889A2 (en) 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
KR101127201B1 (ko) 2003-09-22 2012-04-12 에스*바이오 피티이 리미티드 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
DK1937650T3 (da) * 2005-09-08 2011-10-03 S Bio Pte Ltd Heterocykliske forbindelser
ES2703592T3 (es) * 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
SMT202000168T1 (it) 2012-10-30 2020-05-08 Mei Pharma Inc Terapie di combinazione per il trattamento dei tumori chemioresistenti

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
CN109414425A (zh) 2019-03-01
CO2018012941A2 (es) 2018-12-28
AR108257A1 (es) 2018-08-01
US20200317621A1 (en) 2020-10-08
TW201741286A (zh) 2017-12-01
CA3022011A1 (en) 2017-11-09
JP2019514905A (ja) 2019-06-06
US10626092B2 (en) 2020-04-21
EA201892341A1 (ru) 2019-05-31
SG11201809471UA (en) 2018-11-29
EP3452035B1 (en) 2021-07-07
EP3939966A1 (en) 2022-01-19
PH12018502296B1 (en) 2022-04-06
MX382095B (es) 2025-03-13
KR20190005904A (ko) 2019-01-16
BR112018072439A2 (pt) 2019-02-19
WO2017192451A1 (en) 2017-11-09
MX2018013349A (es) 2019-02-20
ES2886495T3 (es) 2021-12-20
US20190152923A1 (en) 2019-05-23
IL262578A (en) 2018-12-31
EP3452035A1 (en) 2019-03-13
EP3452035A4 (en) 2019-09-25
AU2017261218A1 (en) 2018-11-29
CL2018003109A1 (es) 2019-04-26

Similar Documents

Publication Publication Date Title
CY1126998T1 (el) Πολυμορφικες μορφες rad1901-2hcl
EP3420388A4 (en) PUPILS EQUALIZATION
EP3337486A4 (en) DEUTERIZED CONNECTIONS AND USES THEREOF
HUE059265T2 (hu) Gépjármû felfüggesztés
EP3425126A4 (en) COMMERCIAL VEHICLE
EP3356181A4 (en) IMPROVED VEHICLE
EP3730707B1 (en) FLOOR SIPHON
EP3342646A4 (en) COMMERCIAL VEHICLE
EP3458307C0 (en) FLUID STRESS STABILIZER
HUE055445T2 (hu) Mikrokapszula szuszpenzió
EP4277312C0 (en) SETTING RESERVED SUBFRAMES FOR A RESOURCE GROUP
EP3377897A4 (en) LACTATE BIO SENSORS AND USES THEREOF
EP3025911A4 (en) UP / DOWN STEP OF A COMMERCIAL VEHICLE
EP3459937A4 (en) THIAZONE DERIVATIVE AND APPLICATIONS
EP3713819A4 (en) PENDANT
ITUA20161684A1 (it) Sospensione migliorata
EP3321115A4 (en) VEHICLE WINDOW GLASS
EP3648993C0 (en) VEHICLE SUSPENSION
DK3728208T3 (da) Polymorfer
EP3552872A4 (en) SUSPENSION
EP3383877A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3452035A4 (en) POLYMORPHOUS FORMS OF 3- [2-BUTYL-1- (2-DIETHYLAMINO-EHTYL) -1H-BENZOIMIDAZOLE-5-YL] -N-HYDROXY-ACRYLAMIDE AND USES THEREOF
EP3383401A4 (en) THIENOPYRIMIDINE DERIVATIVES AND USES THEREOF
BR112017003866A2 (pt) membro de suspensão de veículo
EP3354919A4 (en) Fixed constant velocity universal joint